UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000049741
Receipt number R000056658
Scientific Title The effect of romosozumab and denosumab on bone mineral density in patients with rheumatoid arthritis
Date of disclosure of the study information 2022/12/10
Last modified on 2024/02/25 23:14:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of romosozumab and denosumab on bone mineral density in patients with rheumatoid arthritis

Acronym

The effect of romosozumab and denosumab on bone mineral density in patients with rheumatoid arthritis

Scientific Title

The effect of romosozumab and denosumab on bone mineral density in patients with rheumatoid arthritis

Scientific Title:Acronym

The effect of romosozumab and denosumab on bone mineral density in patients with rheumatoid arthritis

Region

Japan


Condition

Condition

rheumatoid arthritis

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Comparison of the effects of romosozumab and denosumab on bone mineral density in patients with rheumatoid arthritis

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Comparison of bone mineral density at one year after administration of the drugs

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

romosozumab 210mg will be administered subcutaneously every month for one year.

Interventions/Control_2

denosumab 60mg will be administered subcutaneously every 6 months for one year.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit

95 years-old >

Gender

Male and Female

Key inclusion criteria

Patients with rheumatoid arthritis and osteoporosis who are outpatients or hospitalized at participating facilities will be subjected to the current study. Patients with severe osteoporosis according to the diagnostic criteria of the Japan Society of Bone and Metabolism and the Japanese Society of Osteoporosis should be included in the romosozumab group. The control denosumab group includes patients with osteoporosis and rheumatoid arthritis for whom bisphosphonates are not sufficiently effective, or patients with severe osteoporosis who need to increase bone density relatively early.

Key exclusion criteria

1. Patients who are not diagnosed with rheumatoid arthritis or osteoporosis.
2. Patients with a history of ischemic heart disease or cerebrovascular disease within the past 1 year are excluded from the romosozumab group.
3.Patients who are allergic to romosozumab or denosumab.
4.Patients who are judged to be unsuitable as subjects by the principal investigator.

Target sample size

70


Research contact person

Name of lead principal investigator

1st name Yuichi
Middle name
Last name Nagase

Organization

Tokyo Metropolitan Tama Medical center

Division name

Department of Rheumatic surgery

Zip code

183-8524

Address

2-8-29, Musashidai, Fuchu

TEL

0423235111

Email

nagaseyuichi17@gmail.com


Public contact

Name of contact person

1st name Yuichi
Middle name
Last name Nagase

Organization

Tokyo Metropolitan Tama Medical center

Division name

Department of Rheumatic surgery

Zip code

183-8524

Address

2-8-29, Musashidai, Fuchu

TEL

0423235111

Homepage URL


Email

nagaseyuichi17@gmail.com


Sponsor or person

Institute

Tokyo Metropolitan Tama medical center

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tokyo Metropoliitan Tama Medical center

Address

2-8-29, Musashidai, Fuchu

Tel

0423235111

Email

nagaseyuichi17@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 12 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

Patients were enrolled to 26 cases in romosozumab group and 24 cases in denosumab group. Data were input to excel and are going to be analyzed.

Results date posted

2023 Year 06 Month 10 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2022 Year 12 Month 10 Day

Date of IRB

2019 Year 10 Month 11 Day

Anticipated trial start date

2022 Year 12 Month 12 Day

Last follow-up date

2026 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 12 Month 10 Day

Last modified on

2024 Year 02 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056658


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name